Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Pınar Akalın; Ayten Yazgan-Karataş

doi:10.1016/j.mex.2023.102372

Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Pınar Akalın^*
, Ayten Yazgan-Karataş

^*Corresponding author for this work

Department of Molecular Biology and Genetics

Istanbul Technical University

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Viral infections continue to pose a significant threat to the public health, leading to high morbidity and mortality rates worldwide. To combat these challenges, early detection and treatment are essential in reducing hospitalizations and preventing severe complications. Simple, inexpensive, and sensitive diagnostic methods are in constant demand in many areas. In this study, we report the development of a nucleic acid-based lateral flow immunoassay device (NALFIA) and demonstrate its successful application in conjunction with a multiplexed reverse-transcription loop-mediated isothermal amplification assay (LAMP) for the detection of SARS-CoV-2 and influenza. In our approach the NALFIA part preparation is independent of the target, and has the potential to ensure widespread use in diagnostics particularly where testing speed is critical such as in respiratory viral infections. • Simple, inexpensive, sensitive and reliable rapid diagnostic tool. • Target independent design. • Effective use for respiratory samples due to practical sample extraction.

Original language	English
Article number	102372
Journal	MethodsX
Volume	11
DOIs	https://doi.org/10.1016/j.mex.2023.102372
Publication status	Published - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors

Funding

This work was funded by Istanbul Technical University Scientific Research Funds (ITU BAP project No: 37702), The Scientific and Technological Research Council of Turkey (TUBITAK) (grant nr. 3205034), and project collaborators Atabay Pharmaceuticals and Fine Chemicals Inc. and Sentromer DNA Technologies Inc. (2021).

Funders	Funder number
Atabay Pharmaceuticals
Fine Chemicals Inc.
Istanbul Technical University Scientific Research Funds
Türkiye Bilimsel ve Teknolojik Araştırma Kurumu	3205034
Bilimsel Araştırma Projeleri Birimi, İstanbul Teknik Üniversitesi	37702

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Diagnostics
Influenza
Loop-Mediated Isothermal Amplification (LAMP)
Nucleic acid lateral flow immunoassay (NALFIA)
U-NALF

Access to Document

10.1016/j.mex.2023.102372

Cite this

@article{80ee9f160b014447bfedb80b6fc630b5,

title = "Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections",

abstract = "Viral infections continue to pose a significant threat to the public health, leading to high morbidity and mortality rates worldwide. To combat these challenges, early detection and treatment are essential in reducing hospitalizations and preventing severe complications. Simple, inexpensive, and sensitive diagnostic methods are in constant demand in many areas. In this study, we report the development of a nucleic acid-based lateral flow immunoassay device (NALFIA) and demonstrate its successful application in conjunction with a multiplexed reverse-transcription loop-mediated isothermal amplification assay (LAMP) for the detection of SARS-CoV-2 and influenza. In our approach the NALFIA part preparation is independent of the target, and has the potential to ensure widespread use in diagnostics particularly where testing speed is critical such as in respiratory viral infections. • Simple, inexpensive, sensitive and reliable rapid diagnostic tool. • Target independent design. • Effective use for respiratory samples due to practical sample extraction.",

keywords = "COVID-19, Diagnostics, Influenza, Loop-Mediated Isothermal Amplification (LAMP), Nucleic acid lateral flow immunoassay (NALFIA), U-NALF",

author = "Pınar Akalın and Ayten Yazgan-Karata{\c s}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = dec,

doi = "10.1016/j.mex.2023.102372",

language = "English",

volume = "11",

journal = "MethodsX",

issn = "2215-0161",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

AU - Akalın, Pınar

AU - Yazgan-Karataş, Ayten

PY - 2023/12

Y1 - 2023/12

N2 - Viral infections continue to pose a significant threat to the public health, leading to high morbidity and mortality rates worldwide. To combat these challenges, early detection and treatment are essential in reducing hospitalizations and preventing severe complications. Simple, inexpensive, and sensitive diagnostic methods are in constant demand in many areas. In this study, we report the development of a nucleic acid-based lateral flow immunoassay device (NALFIA) and demonstrate its successful application in conjunction with a multiplexed reverse-transcription loop-mediated isothermal amplification assay (LAMP) for the detection of SARS-CoV-2 and influenza. In our approach the NALFIA part preparation is independent of the target, and has the potential to ensure widespread use in diagnostics particularly where testing speed is critical such as in respiratory viral infections. • Simple, inexpensive, sensitive and reliable rapid diagnostic tool. • Target independent design. • Effective use for respiratory samples due to practical sample extraction.

AB - Viral infections continue to pose a significant threat to the public health, leading to high morbidity and mortality rates worldwide. To combat these challenges, early detection and treatment are essential in reducing hospitalizations and preventing severe complications. Simple, inexpensive, and sensitive diagnostic methods are in constant demand in many areas. In this study, we report the development of a nucleic acid-based lateral flow immunoassay device (NALFIA) and demonstrate its successful application in conjunction with a multiplexed reverse-transcription loop-mediated isothermal amplification assay (LAMP) for the detection of SARS-CoV-2 and influenza. In our approach the NALFIA part preparation is independent of the target, and has the potential to ensure widespread use in diagnostics particularly where testing speed is critical such as in respiratory viral infections. • Simple, inexpensive, sensitive and reliable rapid diagnostic tool. • Target independent design. • Effective use for respiratory samples due to practical sample extraction.

KW - COVID-19

KW - Diagnostics

KW - Influenza

KW - Loop-Mediated Isothermal Amplification (LAMP)

KW - Nucleic acid lateral flow immunoassay (NALFIA)

KW - U-NALF

UR - https://www.scopus.com/pages/publications/85171323150

U2 - 10.1016/j.mex.2023.102372

DO - 10.1016/j.mex.2023.102372

M3 - Article

AN - SCOPUS:85171323150

SN - 2215-0161

VL - 11

JO - MethodsX

JF - MethodsX

M1 - 102372

ER -

Development of a nucleic acid-based lateral flow device as a reliable diagnostic tool for respiratory viral infections

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this